About Lotus Pharmaceuticals erectile dysfunction.

About Lotus Pharmaceuticals, – Lotus Pharmaceuticals,. controls and operates Liang Fang Pharmaceutical, Ltd erectile dysfunction . and Enze Jiashi Pharmaceutical, Ltd. , two Chinese pharmaceutical company in Beijing. Liang Fang and Enze form a large comprehensive company that, in an integration of the production possessketing of drugs is concerned. Together, they possess some of the most modern pharmaceutical production equipment used in China, workshops by the National GMP, a number of different drugs by Liang Fang and / or encephalopathy produced authenticated, and a number of high-tech personnel. Lotus East has business and office space of 2,000 square meters, a warehouse of 1,000 square meters and operates ten pharmacies in the Beijing area. Lotus East performs scientific research for new drugs and the production, wholesale and retail sale of medicinal products. For more information, please visit.

On extensive clinical studies, isosorbide mononitrate extended release tablet optimistic results in a study of 1,350 patients with angina pectoris who showed the drug for more than six months. Lotus plans the the details the study, and expects that the drug pending the approval from SFDA in 2009 starten.8 million people in China suffer from angina and this number is expected in the coming years due to an aging population is growing. Lotus estimates that it will achieve a 10 percent to 20 percent market share within two years of starting the medication and a market share of 30 percent within three years. And lowers blood pressure. AstraZeneca sells the drug under the trade name Imdur. The components of the drug are matrix tablets, isosorbide mononitrate, and hydroxypropyl methylcellulose . Both components are available at low cost and the tablet is on a large scale on a large scale to to high profit margins for Lotus. ‘We have for the development of in the development of isosorbide mononitrate extended release tablet in both pre-clinical studies and manufacturing capabilities,’said Dr. Zhongyi Liu, Chairman, CEO and President of Lotus Pharmaceuticals, ‘We look forward to the introduction of this drug, the portfolio of our the portfolio of our major drugs diversify ‘.

To patients clinic Views national waiting the target, UK.

Medical Dean Australia and New Zealand is the height Board for the Deans of in the eighteen Australian and two New Zealand healthcare schools and faculties of.